HeartSciences (HSCSW) Net Income towards Common Stockholders (2021 - 2026)

HeartSciences (HSCSW) has reported Net Income towards Common Stockholders for 6 consecutive years, with -$2.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Income towards Common Stockholders fell 31.57% year-over-year to -$2.8 million; the trailing twelve-month figure through Apr 2026 stood at -$9.3 million (down 4.79% YoY), and the FY2026 full-year result was -$9.2 million, down 3.53% from the prior year.
• Net Income towards Common Stockholders retreated to -$2.8 million in Q2 2026 per HSCSW's latest filing, from -$2.4 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$1.2 million in Q1 2022 and bottomed at -$2.8 million in Q2 2026.
• Historically, Net Income towards Common Stockholders has averaged -$1.9 million across 5 years, with a median of -$1.9 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders sank 109.25% in 2022, then increased 20.55% in 2023.
• Over 5 years, Net Income towards Common Stockholders stood at -$1.8 million in 2022, then gained by 3.28% to -$1.7 million in 2023, then slipped by 20.26% to -$2.1 million in 2024, then decreased by 11.9% to -$2.4 million in 2025, then decreased by 17.5% to -$2.8 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$2.8 million, -$2.4 million, and -$2.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.